Transcriptional Shift Identifies a Set of Genes Driving Breast Cancer Chemoresistance

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Vera Ramirez, Laura ^a,b   Sanchez Rovira, Pedro ^a,b   Ramirez Tortosa, Cesar L ^a   Quiles, Jose L ^b,c   Ramirez Tortosa, MCarmen ^b,c   Lorente, Jose A ^b  

^a Department of Oncology Complejo Hospitalario de Jaen ^*  (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Biomedical Research Center CIBM   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TREATMENT RESPONSE; UPREGULATION; VALIDATION PROCESS;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84872238427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053983     Document Type: Article

References (51)

1. Lønning PE, (2010) Molecular basis for therapy resistance. Mol Oncol 4: 284-300.
2. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa CL, Quiles JL, Ramirez-Tortosa MC, et al. (2010) Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach. Cancer Treat Rev 36: 477-484.
3. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN, (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
4. Walther Z, Sklar J, (2011) Molecular tumor profiling for prediction of response to anticancer therapies. Cancer J 17: 71-79.
5. Galanina N, Bossuyt V, Harris LN, (2011) Molecular predictors of response to therapy for breast cancer. Cancer J 17: 96-103.
6. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, et al. (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26: 729-735.
7. Sparano JA, (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7: 347-350.
8. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
9. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616.
10. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, et al. (2010) Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer 126: 2437-2447.
11. Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, et al. (2011) Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 22: 86-92.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
13. Vermeulen L, de Sousa E Melo F, Richel DJ, Medema JP, (2012) The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 13: e83-e89.
14. Kakarala M, Wicha MS, (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26: 2813-2820.
15. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783.
16. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
17. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 2006;314, 268-274.
18. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, et al. (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12: 320-327.
19. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
20. Chang HR, (2010) Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 116: 2856-2867.
21. Drury S, Anderson H, Dowsett M, (2009) Selection of REFERENCE genes for normalization of qRT-PCR data derived from FFPE breast tumors. Diagn Mol Pathol 18: 103-107.
22. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646-674.
23. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS, (2011) Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 27 13: 212-226.
24. Sparano JA, Paik S, (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26: 721-728.
25. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, et al. (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26: 729-735.
26. Weigelt B, Reis-Filho JS, (2010) Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res 12Suppl 4: S5.
27. Reis-Filho JS, Pusztai L, (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378: 1812-1823.
28. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
29. Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, et al. (2008) Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 214: 357-367.
30. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15: 68-74.
31. Derleth C, Mayer IA, (2010) Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 10(Suppl 1): E23-31.
32. Korkaya H, Liu S, Wicha MS, (2011) Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancers Inflammatory Roots. Clin Cancer Res 17(19): 6125-6129.
33. Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, et al. (2008) Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26: 1818-1830.
34. Kakarala M, Wicha MS, (2007) Cancer stem cells: implications for cancer treatment and prevention. Cancer J 13: 271-275.
35. Polyak K, Weinberg RA, (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
36. Berx G, Van Roy F, (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 3: 289-293.
37. López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, et al. (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 19: 301-309.
38. Foubert E, De Craene B, Berx G, (2010) Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res. 12: 206-217.
39. Foroni C, Broggini M, Generali D, Damia G, (2012) Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev. 38: 689-697.
40. Incassati A, Chandramouli A, Eelkema R, Cowin P, (2010) Key signaling nodes in mammary gland development and cancer: β-catenin. Breast Cancer Res. 12: 213-227.
41. Lai SL, Chien AJ, Moon RT, (2009) Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res. 19: 532-45.
42. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, et al. (2011) Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit Rev Oncol Hematol. 80: 347-368.
43. Wilson WR, Hay MP, (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer. 11: 393-410.
44. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, et al. (2010) Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. Plos One. 5: e12038.
45. Hao J, Song X, Song B, Liu Y, Wei L, et al. (2008) Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther. 15: 449-455.
46. Ke X, Fei F, Chen Y, Xu L, Zhang Z, et al. (2012) Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. Carcinogenesis 33: 1598-607.
47. Otto T, Fandrey J, (2008) Thyroid hormone induces hypoxia-inducible factor 1alpha gene expression through thyroid hormone receptor beta/retinoid x receptor alpha-dependent activation of hepatic leukemia factor. Endocrinology. 149: 2241-2250.
48. Cannito S, Novo E, Compagnone A, Valfrè di Bonzo L, Busletta C, et al. (2008) Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29: 2267-2278.
49. Louie E, Nik S, Chen JS, Schmidt M, Song B, et al. (2010) Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res. 12: R94.
50. Han M, Wang Y, Liu M, Bi X, Bao J, et al. (2012) MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 103: 1058-1064.
51. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, et al. (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 109: 2784-2789.